Evozyne
Steve Mayo is a distinguished academic and industry leader, currently serving as the Bren Professor of Biology and Chemistry and Merkin Institute Professor at Caltech since September 1992. Mayo holds board positions at Merck, Sarepta Therapeutics, and Allogene Therapeutics, all beginning in 2021 and 2022, respectively. As a co-founder of Protabit since 2009 and Xencor in 1997, Mayo has significant entrepreneurial experience in biotechnology. Educational credentials include a Ph.D. in Chemistry from Caltech and postdoctoral training in Biochemistry at Stanford University School of Medicine and Chemistry at the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
Evozyne
1 followers
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.